Wong C A, Scavone B M, Loffredi M, Wang W Y, Peaceman A M, Ganchiff J N
Department of Anesthesiology, Section of Obstetric Anesthesiology, Section of Maternal-Fetal Medicine, Northwestern University Medical School, Chicago, Illinois 60611, USA.
Anesthesiology. 2000 Jun;92(6):1553-8. doi: 10.1097/00000542-200006000-00011.
Regional analgesia for labor often is initiated with an intrathecal injection of a local anesthetic and opioid. The purpose of this prospective, randomized, blinded study was to determine the optimal dose of intrathecal sufentanil when combined with 2.5 mg bupivacaine for labor analgesia.
One hundred seventy parous parturients with cervical dilation between 3-5 cm were randomized to receive intrathecal 0 (control), 2.5, 5.0, 7.5, or 10.0 microg sufentanil combined with 2.5 mg bupivacaine, followed by a lidocaine epidural test dose, for initiation of analgesia (34 patients in each group). Visual analog scores and the presence of nausea, vomiting, and pruritus were determined every 15 min until the patient requested additional analgesia. Fetal heart rate tracings were compared between groups.
Groups were similar for age, height, weight, oxytocin dose, duration of labor, and baseline visual analog scores. Duration of action was significantly shorter for control patients (39 +/- 25 min [mean +/- SD]) compared with those administered sufentanil, all doses (93 +/- 32, 93 +/- 47, 94 +/- 33, 97 +/- 39 min), but was not different among groups administered 2.5, 5.0, 7.5, or 10.0 microg sufentanil. More patients who received 10 microg sufentanil reported nausea and vomiting than did control patients. The severity of pruritus increased with administration of 7.5 and 10.0 microg sufentanil. There was no difference in fetal heart rate changes among groups.
Intrathecal bupivacaine (2.5 mg) without sufentanil did not provide satisfactory analgesia for parous patients. However, bupivacaine combined with 2.5 microg sufentanil provided analgesia comparable to higher doses, with a lower incidence of nausea and vomiting and less severe pruritus.
分娩区域镇痛通常通过鞘内注射局部麻醉药和阿片类药物开始。这项前瞻性、随机、双盲研究的目的是确定鞘内注射舒芬太尼与2.5mg布比卡因联合用于分娩镇痛时的最佳剂量。
170例宫颈扩张3-5cm的经产妇被随机分为接受鞘内注射0(对照组)、2.5、5.0、7.5或10.0μg舒芬太尼联合2.5mg布比卡因,随后给予利多卡因硬膜外试验剂量,以开始镇痛(每组34例患者)。每15分钟测定视觉模拟评分以及恶心、呕吐和瘙痒的发生情况,直至患者要求追加镇痛。比较各组间的胎儿心率描记图。
各组在年龄、身高、体重、缩宫素剂量、产程和基线视觉模拟评分方面相似。与所有剂量舒芬太尼组(93±32、93±47、94±33、97±39分钟)相比,对照组患者的作用持续时间显著缩短(39±25分钟[平均值±标准差]),但在给予2.5、5.0、7.5或10.0μg舒芬太尼的组间无差异。接受10μg舒芬太尼的患者比对照组更多地报告恶心和呕吐。随着7.5和10.0μg舒芬太尼的给药,瘙痒严重程度增加。各组间胎儿心率变化无差异。
鞘内注射不含舒芬太尼的布比卡因(2.5mg)不能为经产妇提供满意的镇痛效果。然而,布比卡因联合2.5μg舒芬太尼提供的镇痛效果与更高剂量相当,恶心和呕吐发生率较低,瘙痒程度较轻。